CTMC specializes in the development and commercialization of cell therapies, particularly focusing on innovative solutions for cancer treatment. By integrating advanced biopharmaceutical manufacturing technologies with the clinical expertise of MD Anderson Cancer Center, CTMC aims to accelerate the translation of scientific breakthroughs into effective therapies. The organization operates within a state-of-the-art facility that includes a 60,000 square foot cGMP cleanroom, designed specifically for cell therapy development. This infrastructure supports a data-rich environment that enhances the efficiency of clinical trials and patient care, ensuring that novel therapies can be developed and tested rapidly.

The team at CTMC comprises experienced professionals from both industry and academia, which fosters a deep scientific understanding of cell therapy processes. Their approach emphasizes Quality by Design, ensuring that every aspect of therapy development is rigorously evaluated and optimized for commercialization. By collaborating closely with manufacturing technology experts and clinical leaders, CTMC is positioned to deliver first-in-human therapies that demonstrate their potential effectively and efficiently. This commitment to innovation and quality aims to make a significant impact on cancer treatment, ultimately striving for the goal of single-dose cures.

United States

CTMC is a joint venture between Resilience and MD Anderson Cancer Center. We bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy's impact for cancer patients.

CTMC

Company Details